Pharmacokinetics of Ampicillin and Sulbactam in Pediatric Patients

Author:

Nahata Milap C.1,Vashi Vijay I.2,Swanson Robert N.2,Messig Michael A.2,Chung Menger2

Affiliation:

1. The Ohio State University College of Pharmacy and Children’s Hospital, Columbus, Ohio,1and

2. Pfizer Central Research, New York, New York2

Abstract

ABSTRACT Intravenous ampicillin-sulbactam is effective in the treatment of various infections in adults, but little is known about the pharmacokinetics (PK) of ampicillin-sulbactam in children. The objective of this study was to determine the PK of ampicillin and sulbactam in pediatric patients with intra-abdominal infection, skin and/or skin structure infection, or periorbital-preseptal and facial cellulitis. Intravenous ampicillin and sulbactam (2:1), 40 to 80 mg/kg of body weight, were given every 6 h for 2 to 6 days to 28 pediatric patients. The ages ranged from 1 to 6 years for 10 patients, 6.1 to 10 years for 9 patients, and 10.1 to 12 years for 9 patients. Multiple blood samples were obtained and analyzed for ampicillin and sulbactam in plasma and serum by high-performance liquid chromatography. The mean maximum concentration of drug in serum ranged from 177 to 200 μg/ml for ampicillin and 82 to 102 μg/ml for sulbactam in the three age groups. The mean total clearance, steady-state distribution volume, and half-life were 4.76 ml/min/kg, 0.32 liter/kg, and 0.77 h, respectively, for ampicillin and 4.95 ml/min/kg, 0.34 liter/kg, and 0.81 h, respectively, for sulbactam. Dose or gender did not affect the PK of ampicillin or sulbactam. The PK of ampicillin and sulbactam in these patients were comparable to those reported in adults. The combination was well tolerated in pediatric patients.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference24 articles.

1. Clinical pharmacology of antimicrobials in premature infants. II. Ampicillin, methicillin, oxacillin, neomycin and colistin.;Axline S. G.;Pediatrics,1967

2. Sulbactam/ampicillin, a new beta-lactamase inhibitor/beta-lactam antibiotic combination.;Benson J.;Drug Intell. Clin. Pharm.,1988

3. FDA, 21CFR. Part 201 (docket no. 92N0165). Specific requirements on the content and format of labeling for human prescription drugs: revision of “Pediatric Use” subsection in the laboratory.;Federal Register;Fed. Regist.,1994

4. Pharmacokinetics of sulbactam/ampicillin in humans: a review.;Foulds G.;J. Infect. Dis.,1991

5. Bacteriological, pharmacokinetic and clinical studies of sulbactam/ampicillin in the pediatric field.;Haruta T.;Jpn. J. Antibiot.,1989

Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3